Ignite Creation Date:
2024-05-06 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06202820
Status:
RECRUITING
Last Update Posted:
2024-02-28
First Post:
2024-01-01
Brief Title:
CV CARE CardioVascular Care in PC Patients
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
CV CARE CardioVascular Care of Androgen Related Effects in Prostate Cancer Patients
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research is being done to test a program to assess and manage reversible cardiovascular CV risk factors in participants with prostate cancer starting androgen deprivation therapy ADT with the goal of integrating a standardized method into Dana-Farber Cancer Institute clinics for all such participants
The name of the intervention used in this research study is
CV Care cardiovascular risk assessment and management program
The name of the intervention used in this research study is
CV Care cardiovascular risk assessment and management program
Detailed Description:
This research is being done to test a program to assess and manage reversible cardiovascular CV risk factors in participants with prostate cancer starting androgen deprivation therapy ADT with the goal of integrating a standardized method into Dana-Farber Cancer Institute clinics for all such participants
Study procedures including screening for eligibility treatment visits questionnaires and surveys and blood and urine tests
Participation in this research study is expected to last about 6 months
It is expected that about 60-150 people will take part in this study
This study is supported by the National Comprehensive Cancer Network NCCN through grant funding provided by Pfizer Myovant
Study procedures including screening for eligibility treatment visits questionnaires and surveys and blood and urine tests
Participation in this research study is expected to last about 6 months
It is expected that about 60-150 people will take part in this study
This study is supported by the National Comprehensive Cancer Network NCCN through grant funding provided by Pfizer Myovant
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None